newsfilter
← Latest News
GlobeNewswire·

Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

  • Century Therapeutics is advancing CNTY-813, a beta islet cell therapy for type 1 diabetes, through IND-enabling studies with an expected IND submission in the fourth quarter of 2026 & initial clinical data anticipated in the second half of 2027.
  • CNTY-308, a CD19-targeted CAR-iT cell therapy utilizing Allo-Evasion™ 5.0, is on track to enter clinical trials in 2026 following progress in IND-enabling studies.
  • The company completed an oversubscribed $135 million private placement in January 2026, extending its cash runway into the first quarter of 2029.
  • Full-year 2025 collaboration revenue with Bristol-Myers Squibb totaled $109.2 million, a significant increase from $6.6 million in 2024.
  • Research & development expenses for 2025 were $95.7 million, down from $107.2 million in 2024, while general & administrative expenses decreased to $24.0 million from $33.2 million.
  • The company reported a net loss of $9.6 million for the year ended December 31, 2025, compared to a net loss of $126.6 million in 2024.
  • Cash, cash equivalents, & marketable securities stood at $117.1 million as of December 31, 2025.
  • Han Lee, Ph.D., M.B.A., & Martin Murphy, Ph.D., were appointed to the Board of Directors in December 2025.
  • Additional clinical insights from the ongoing CARAMEL IST trial involving CNTY-101 are expected in 2026.